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memory phenotypes via epigenetic 
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Chronic inflammation facilitates tumor progression. We discovered that a subset of non-small cell 
lung cancer cells underwent a gradually progressing epithelial-to-mesenchymal (EMT) phenotype 
following a 21-day exposure to IL-1β, an abundant proinflammatory cytokine in the at-risk for lung 
cancer pulmonary and the lung tumor microenvironments. Pathway analysis of the gene expression 
profile and in vitro functional studies revealed that the EMT and EMT-associated phenotypes, including 
enhanced cell invasion, PD-L1 upregulation, and chemoresistance, were sustained in the absence of 
continuous IL-1β exposure. We referred to this phenomenon as EMT memory. Utilizing a doxycycline-
controlled SLUG expression system, we found that high expression of the transcription factor SLUG 
was indispensable for the establishment of EMT memory. High SLUG expression in tumors of lung 
cancer patients was associated with poor survival. Chemical or genetic inhibition of SLUG upregulation 
prevented EMT following the acute IL-1β exposure but did not reverse EMT memory. Chromatin 
immunoprecipitation and methylation-specific PCR further revealed a SLUG-mediated temporal 
regulation of epigenetic modifications, including accumulation of H3K27, H3K9, and DNA methylation, 
in the CDH1 (E-cadherin) promoter following the chronic IL-1β exposure. Chemical inhibition of 
DNA methylation not only restored E-cadherin expression in EMT memory, but also primed cells for 
chemotherapy-induced apoptosis.
Dysregulated inflammation is recognized as one of the hallmarks of cancer and is involved in tumor initiation, 
progression, and metastasis1–3. Chronic inflammatory conditions, such as chronic obstructive pulmonary disease 
or ulcerative colitis, are strongly associated with elevated cancer incidence4–6. Chronic use of aspirin or other 
non-steroidal anti-inflammatory drugs reduces mortality of esophageal, colorectal, and lung cancers7,8.
Interleukin-1 beta (IL-1β), a proinflammatory cytokine, correlates with tumor progression in non-small 
cell lung cancer (NSCLC) patients in multiple studies. Wu et al. found an elevated level of serum IL-1β in 
NSCLC patients compared to healthy donors. Elevated IL-1β in these patients is associated with poor survival9. 
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A similar conclusion was drawn in an independent study showing that elevated serum IL-1β correlates with 
poor progression-free survival in NSCLC patients10. In another study investigating tumor-associated inflamma-
tory responses in early stage lung cancer, high levels of IL-1β were found to be associated with 3-year mortality 
in adenocarcinoma11. Consistent with these findings, the abundance of IL-1 receptor antagonist is associated 
with a decreased lung cancer risk in a nested case-control study12. Particularly noteworthy, the Canakinumab 
Anti-inflammatory Thrombosis Outcomes Study (CANTOS) revealed that IL-1β inhibition with the neutralizing 
antibody canakinumab decreases both the incidence and mortality of lung cancer in patients with atherosclerosis 
co-morbidities13. Although our previous studies and those from others demonstrated that acute IL-1β exposure 
induces the expression of genes associated with transformation, invasion, and metastasis in multiple malignan-
cies, including lung cancer, the impact of chronic IL-1β exposure, which may be more physiologically relevant, 
has not yet been defined14–20.
Metastasis is the primary cause of cancer-related mortality3,21,22. Epithelial-to-mesenchymal transition (EMT) 
plays a critical role in cancer metastasis because it endows metastatic cells with migratory and invasive proper-
ties, apoptosis resistance, and immune evasion23. In addition, successful colonization in distant organs requires 
mesenchymal-to-epithelial transition (MET)24. The EMT program can be activated in response to pathologic sig-
nals such as inflammatory cytokines in the primary tumor microenvironment (TME). However, the mechanisms 
by which metastatic cells maintain the mesenchymal properties following detachment from the primary tumor 
and subsequently regain the epithelial status to form macrometastases are unknown.
Here, we define “EMT memory” as a prolonged EMT program induced by chronic IL-1β exposure in NSCLC 
cells in which EMT features persist in the absence of the inflammatory signal. We identify a unique pattern of 
epigenetic modifications that leads to the formation of EMT memory. This study reveals distinct molecular events 
modulating acute and chronic inflammation, thus enhancing our understanding of the temporal-spatial regula-
tion of EMT during metastasis.
Results
Chronic cytokine exposure leads to EMT memory in NSCLC. Because IL-1β and IL-1β-induced 
genes have been implicated in promoting lung tumor progression in multiple experimental settings and human 
specimens10,14–16,25, we sought to examine whether IL-1β induced EMT in NSCLC. When exposed to IL-1β (1 ng/
ml) for 48 hours, A549 lung cancer cells displayed a disaggregated growth pattern with increased cell protru-
sions, indicating a mesenchymal phenotype (Fig. S1A). Downregulation of several epithelial markers including 
E-cadherin, gamma-catenin, and cytokeratin 18 (CK18), and upregulation of vimentin, a mesenchymal marker, 
were confirmed in these cells by immunoblotting (Fig. 1A). Other mesenchymal markers, such as N-cadherin, 
smooth muscle actin (SMA), and Fibronectin, were also upregulated (Fig. S1B). Because chronic inflammation 
may play a greater role during tumor development than acute inflammation, we next investigated the impact of 
chronic IL-1β exposure on these tumor cells (Fig. 1B). When exposed to IL-1β for 21 days, A549 cells acquired a 
gradually progressing mesenchymal phenotype, as evidenced by changes in both cell morphology and molecular 
markers (Fig. 1C,D). Of note, following IL-1β withdrawal, these mesenchymal features were maintained for at 
least 30 days before reverting to the pretreatment epithelial state. We designated this prolonged yet reversible 
EMT program in the absence of the original inflammatory stimulus “EMT memory.” EMT memory appeared to 
be IL-1β-exposure time-dependent because shorter exposure time (3-, 6-, or 9-day exposure) did not lead to EMT 
memory (Figs. 1E and S1C). In addition, a ten-fold increase in IL-1β concentration (10 ng/ml) did not accelerate 
the EMT memory formation (Fig. S1C).
To determine whether EMT memory was unique to IL-1β stimulation, we chronically exposed A549 cells to 
TNF-α or TGF-β, two other inflammatory cytokines that are commonly found in the lung TME. Similarly, both 
cytokines were found to induce EMT memory (Fig. 1F). We also screened an additional ten NSCLC cell lines for 
IL-1β response and found that two of these cell lines, A427 and H460, had EMT changes in at least two of the 
examined markers following a 48-hour IL-1β exposure and demonstrated a prolonged EMT phenotype following 
a 21-day IL-1β exposure (Fig. S1D–F). The EMT memory phenotype in A427 and H460 was evident and endured 
for 12 to 18 days. This shorter duration of EMT memory may be related to the lack of potential for further mes-
enchymal transition in these two lines as their baseline E-cadherin expression was not detectable (Fig. S1D,E).
EMT-associated phenotypes induced by chronic IL-1β exposure are also memorized. Given 
the known pleiotropic effects of EMT, we characterized several key EMT-associated phenotypes in the model 
of IL-1β exposure in A549 cells. First, the cellular proliferation rate decreased following IL-1β exposure in 
2-dimensional cell culture (Fig. 2A). To better assess the tumorigenic potential of these cells, we evaluated the 
anchorage-independent growth (AIG) in a 3-dimensional assay as previously described26. Cells formed fewer and 
smaller colonies in semisolid medium following both the chronic IL-1β exposure and EMT memory, indicating 
an impaired potential for solid tumor formation (Fig. 2B). This result is consistent with previous findings showing 
that mesenchymal cells proliferate more slowly compared to their epithelial counterparts, and MET is required 
for establishing metastatic lesions27,28. Second, IL-1β-treated cells acquired apoptosis resistance to chemother-
apy agents, including cisplatin, etoposide, doxorubicin, and vorinostat (SAHA) (Fig. 2C). Third, we evaluated 
PD-L1 expression because previous studies demonstrated a correlation between a mesenchymal signature and 
elevated expression of immune checkpoint proteins in human NSCLC29,30. We found increased PD-L1 levels in 
these IL-1β-treated cells (Fig. 2D). Notably, the chronic IL-1β exposure led to more pronounced EMT-associated 
phenotypes compared to the acute IL-1β exposure. Following the chronic IL-1β exposure, these phenotypes were 
sustained for at least 7 days after IL-1β withdrawal. In addition, we found chemoresistance and PD-L1 upregula-
tion in H460 and chemoresistance in A427 following the acute IL-1β exposure (Fig. S2A,B).
Given the robust EMT and EMT-associated memory phenotypes in A549 cells, we characterized the underly-
ing molecular events in A549 cells by RNA sequencing. Compared to the untreated control cells, 741 genes were 
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differentially expressed at more than one time point in the presence of IL-1β and formed four clusters (Fig. S2C 
and Table S1). The vast majority of genes in cluster 1 (upregulated genes) and 4 (downregulated genes) were 
sensitive to IL-1β, so that their expression returned to the base line immediately upon IL-1β withdrawal. Many of 
the genes in these two clusters are cytokines, chemokines, and regulatory proteins involved in inflammation and 
immune response (e.g. CXCL8, CCL2, TGFB1 and MAP4K1). However, gene expression in cluster 2 (upregulated 
genes) and 3 (downregulated genes) exhibited a memory pattern in which the deregulation remained for at least 
Figure 1. Chronic cytokine exposure leads to EMT memory in NSCLC. (A) A549 cells underwent EMT upon 
48-hour IL-1β (1 ng/ml) exposure. (B) Experimental design for the chronic IL-1β treatment: A549 cells were 
exposed to IL-1β for 21 days and subsequently cultured for 30 days after IL-1β withdrawal. Cells were split every 
three to four days with fresh IL-1β in the medium. (C) Morphological changes of the untreated and treated 
A549 cells with IL-1β by bright-field microscopy at different time points. (D) EMT markers in A549 cells were 
determined by immunoblotting following the time course. Quantification of each marker was normalized to 
the untreated samples. (E) EMT was reversed within 6 days upon IL-1β withdrawal following 3 days or 6 days 
of IL-1β treatment in A549 cells. (F) A549 cells chronically treated with TNF-α (10 ng/ml) or TGF-β (5 ng/ml) 
for 21 days were examined for EMT and EMT memory. “-d”, days after IL-1β withdrawal; “p”, previously treated 
with IL-1β. “n.d.”, non-detectable. “Tα”, TNF-α; “Tβ”, TGF-β; “pTα”, previously treated with TNF-α; “pTβ”, 
previously treated with TGF-β. See also Fig. S1.
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30 days following IL-1β removal. These genes encode many proteins involved in integrin cell surface interactions, 
extracellular matrix organization, invasion, and immune checkpoints (e.g. ITGB3, RUNX2, SMAD6, FOXA1 and 
CD274), in addition to the key EMT markers such as CLDN2 and CDH1 (Fig. S2C and Table S1).
We then performed the pathway analysis of the whole transcriptome to determine if genes involved in the 
same pathway revealed concurrent alterations in expression. Among 10,611 gene sets/pathways available in the 
Molecular Signature Database31, 555 were found to be deregulated by IL-1β stimulation. Approximately 48% of 
these exhibited memory effect and persisted for more than half of their peak activities for 15 days following IL-1β 
withdrawal, while the remainder of the pathways were identified as IL-1β sensitive pathways as their activities 
readily reversed following IL-1β withdrawal (Table S2). IL-1β exposure immediately deregulated many signa-
ling pathways, including the AP-1, NF-κB, JNK, and AKT pathways, as well as cellular programs, such as cell 
migration and differentiation. The activities of these pathways were sensitive to IL-1β (Fig. S2D and Table S2). 
Figure 2. EMT-associated phenotypes induced by chronic IL-1β exposure are also memorized. (A) Growth 
curve of A549 cells with various IL-1β treatments, normalized to the value on day 0 on each condition. (B) A 
dot plot showing numbers of colonies at day 14 after A549 cells were plated for anchorage-independent growth 
(AIG). Each dot represents a duplicate well. (C) Apoptotic markers were evaluated 24 hours after A549 cells 
were treated with chemotherapy agents. Quantification of cleaved PARP (c’-PARP) and Caspase 3 (c’-Caspase 
3) was normalized to samples without IL-1β exposure. (D) Surface PD-L1 expression was assessed by flow 
cytometry. Quantification from 3 replicates is represented in the bar graph. (E) Pathway analysis of EMT-
associated biological processes at different time points. (F) A pie chart summarizing EMT memory phenotypes. 
“A”, acute IL-1β exposure (72 hours); “C”, chronic IL-1β exposure (≥21 days); “M”, EMT memory (≥7 days 
after IL-1β withdrawal from chronic exposure). Cis, cisplatin; Etop, etoposide; Doxr, doxorubicin. “n.d.”, non-
detectable. All results are reported as mean ± SEM. ****P < 0.0001. See also Fig. S2, Tables S1 and S2.
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Consistent with the observed mesenchymal morphologies, genes involved in EMT showed significantly upregu-
lated expression within seven days of treatment, further increased during the chronic treatment, and were main-
tained at high levels for 30 days following IL-1β withdrawal (Fig. 2E). In addition to EMT, the chronic IL-1β 
exposure also increased and maintained expression of genes related to cell adhesion, cancer invasion, apoptosis 
resistance, and production of cytokines involved in immune responses (Fig. 2E and Table S2). In summary, IL-1β 
induces EMT-associated phenotypes in NSCLC cell lines, including decreased proliferation, enhanced invasion, 
resistance to cell death, and PD-L1 upregulation, all of which are memorized following chronic IL-1β exposure 
(Fig. 2F).
Based on the status of IL-1β exposure, we divided EMT into three phases: (i) acute EMT, in which cells are 
exposed to IL-1β for fewer than 7 days; (ii) chronic EMT, in which cells are exposed to IL-1β for at least 21 days; 
and (iii) EMT memory, in which cells are cultured in the absence of IL-1β after chronic EMT is established.
Accumulation of SLUG is indispensable for the establishment of the memory pheno-
types. Following the acute IL-1β exposure, RNA sequencing revealed upregulation of two EMT transcrip-
tion repressors, SLUG and ZEB2 (Table S1). RT-PCR confirmed that the expression of SLUG and ZEB2, but not 
SNAI1, ZEB1, or TWIST1, increased in A549 cells (Fig. S3A). Of mechanistic importance, knockdown of SLUG 
or ZEB2 was sufficient to abolish the downregulation of E-cadherin in acute EMT (Fig. S3B). In chronic EMT, 
SLUG expression dramatically increased with continous IL-1β exposure (up to 9-fold) whereas ZEB2 was only 
upregulated less than 4-fold (Fig. 3A). Therefore, we hypothesized that the elevated SLUG expression was essen-
tial for the establishment of chronic EMT and EMT memory. To test this hypothesis, we generated A549 cells 
expressing doxycycline (Dox)-inducible SLUG shRNA and partially knocked down SLUG after an initial 7-day 
IL-1β exposure by addition of Dox from day 8 to day 21 (Fig. 3B). These cells were designated as “low SLUG” (LS), 
compared to cells maintaining the endogenous levels of SLUG without knockdown, designated as “high SLUG” 
(HS). Whereas HS cells demonstrated a steadily increased SLUG expression up to 21 days of IL-1β exposure, 
this upregulation was abolished after 7 days of IL-1β exposure in LS cells. Both SLUG mRNA and protein levels 
in LS cells reversed rapidly to the base line after IL-1β withdrawal (Fig. 3C,D). Consistently, LS cells displayed a 
less profound mesenchymal morphology in chronic EMT compared to HS cells, and readily reversed to the epi-
thelial features (Fig. S3C). A complete reversal of E-cadherin expression in LS cells at day 7 of IL-1β withdrawal 
confirmed an impaired EMT memory phenotype (Fig. 3D). In addition, apoptosis resistance and elevated PD-L1 
expression were also readily reversed in LS cells (Fig. 3E,F). These data indicate that IL-1β-induced high SLUG 
expression is indispensable for the establishment of chronic EMT and EMT memory.
To assess whether high SLUG level was sufficient to induce these memory phenotypes, we generated A549 cells 
overexpressing various levels of SLUG controlled by Dox. Cells highly overexpressing SLUG harbored the most 
profound EMT phenotype, highest apoptosis resistance, and highest PD-L1 expression. These phenotypes were 
memorized for at least 7 days following the termination of SLUG overexpression. In contrast, cells with moderate 
SLUG expression demonstrated moderate EMT and impaired memory phenotypes (Fig. S3D–G). These findings 
suggest that SLUG alone can establish both EMT and EMT memory phenotypes in a concentration-dependent 
manner. To investigate the potential clinical relevance of these findings, we performed Kaplan-Meier analysis 
using the TCGA database and found that high SLUG expression in lung adenocarcinoma patients was associ-
ated with poor prognosis (Fig. 3G). Two mesenchymal markers, SMA and Fibronectin, were also more highly 
expressed in these patients with high SLUG expression tumors (Fig. 3H).
Pathways mediating acute EMT are not required for the maintenance of chronic EMT or 
EMT memory. Next, we sought to delineate the molecular events upstream of SLUG in the regulation of 
IL-1β-induced EMT in A549 cells. IL-1β activated the MAPK (ERK, JNK, and p38), AKT, and NF-κB signaling 
pathways within 48 hours of treatment (Fig. S4A). Reagents inhibiting the ERK or JNK pathway, impaired the 
downregulation of E-cadherin in acute EMT (Fig. 4A). This inhibition was concentration-dependent (Fig. S4B). 
Among the downstream targets of the ERK and JNK pathways, we found that Fra-1 and c-JUN, were phos-
phorylated and upregulated in response to IL-1β, leading to the formation of the transcription factor AP-1 by 
dimerization (Fig. S4C,D). Transient knockdown of Fra-1 prevented the upregulation of SLUG and subsequent 
acute EMT (Fig. 4B). The JNK inhibitor II abolished the upregulation of Fra-1, SLUG, and ZEB2 (Fig. S4E). These 
data suggest activation of the JNK - AP-1 - SLUG signaling pathway following the acute IL-1β exposure. Thus, 
we have identified that the MAPK (ERK and JNK) - AP-1 - SLUG axis mediates the IL-1β-induced acute EMT in 
A549 cells (Fig. 4C).
Because SLUG expression and ERK phosphorylation remained elevated in both chronic EMT and EMT mem-
ory compared to the untreated cells (Figs. 3A and S4F), we anticipated that the MAPK (ERK and JNK) - AP-1 
- SLUG axis was also required to maintain chronic EMT and EMT memory. Therefore, we hypothesized that inhi-
bition of this axis should reverse the mesenchymal features in the EMT memory cells. However, genetic or chem-
ical inhibition of the MAPK (ERK and JNK) - AP-1 - SLUG axis for 48 hours in EMT memory failed to reverse 
the expression of the EMT markers (Fig. 4D,E). Furthermore, extension of Fra-1 knockdown for 14 days in EMT 
memory did not alter the expression of the EMT markers (Fig. 4F). Similar findings were found in cells with 
chronic EMT (Fig. S4G). These results indicate that the MAPK (ERK and JNK) - AP-1 - SLUG axis is not required 
for E-cadherin suppression in either chronic EMT or EMT memory once the suppression is established, consist-
ent with the findings that EMT phenotypes are maintained even after the SLUG overexpression is terminated 
(Fig. S3D–G). Moreover, we re-exposed cells to IL-1β in EMT memory to determine if this re-stimulation would 
restore the molecular features of EMT. In contrast to the cells in acute EMT, IL-1β re-exposure failed to further 
decrease E-cadherin in cells with EMT memory despite activation of ERK signaling, indicating that E-cadherin 
suppression is memorized and cannot be altered by additional stimulation (Fig. 4G). Similarly, we determined 
that the NF-κB inhibition by p65 knockdown strongly sensitized cells to apoptosis in response to cisplatin and 
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doxorubicin in acute EMT. However, this inhibition achieved minimal “rescue” effects in chronic EMT and EMT 
memory (Fig. 4H). These results suggest that the NF-κB pathway is more critical for apoptosis resistance in acute 
EMT than chronic EMT and EMT memory. Together, these findings indicate that the pathways mediating the 
acute EMT phenotypes are not necessarily required to maintain the chronic EMT and EMT memory phenotypes.
Dynamic epigenetic modifications of the CDH1 promoter in IL-1β-induced EMT. Epigenetic 
modifications can regulate epithelial gene expression during EMT, leading to either long-term silencing or 
disinhibition of these genes during MET28. We found that once established, IL-1β-induced EMT memory was 
Figure 3. Accumulation of SLUG is indispensable for the establishment of the memory phenotypes. (A) A 
crescendo expression pattern of SLUG and ZEB2 upon the chronic IL-1β exposure in A549 cells, followed by a 
decrescendo pattern after IL-1β withdrawal, determined by RT-qPCR. (B) Experimental design: in LS group, 
doxycycline was added to induce SLUG shRNA after 7 days of IL-1β treatment and removed together with 
IL-1β at day 21. (C) Relative SLUG expression by RT-qPCR in LS and HS cells compared to the untreated cells. 
(D–F) EMT markers, apoptosis resistance, and surface PD-L1 expression were evaluated in different EMT 
stages in LS and HS cells compared to the IL-1β-untreated cells. (G) Kaplan-Meier curves from the TCGA 
lung adenocarcinoma (LUAD) cohort showing the survival probability in patients with various levels of SLUG 
expression. (H) Expression of SMA and Fibronectin in the same cohort of patients (95% confidence interval). All 
results are reported as mean ± SEM unless indicated otherwise. ***P < 0.0002, ****P < 0.0001. See also Fig. S3.
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maintained independent of the MAPK (ERK and JNK) - AP-1 - SLUG axis. Therefore, we hypothesized that epi-
genetic machinery, including histone modifications and DNA methylation, may mediate EMT memory. Because 
downregulation of E-cadherin (CDH1) is a direct function of SLUG and a hallmark of EMT, we focused on inves-
tigating the epigenetic modifications of the CDH1 promoter in A549 cells.
Figure 4. Pathways mediating acute EMT are not required for the maintenance of chronic EMT or EMT 
memory. (A) E-cadherin expression following 48 hours of chemical inhibition of IL-1β-activated signaling 
pathways. (B) A549 cells were exposed to IL-1β for 48 hours following Fra-1 knockdown and examined for 
EMT markers. (C) A schematic mechanism of the IL-1β-induced acute EMT in A549 cells. (D) Evaluation of 
EMT markers with 48-hour inhibition of the MAPK (ERK and JNK) - AP-1 - SLUG axis in EMT memory. (E) 
Expression of SLUG, ZEB2, Fra-1, and JUN upon the JNK inhibition in EMT memory (-7d). (F) Expression of 
EMT markers with 14 days of Fra-1 knockdown (KD) following IL-1β withdrawal from the chronic treatment. 
(G) E-cadherin level and ERK signaling activity in A549 cells when being re-exposed to IL-1β after either 
14 days of IL-1β withdrawal in EMT memory or 7 days of IL-1β exposure in acute EMT. (H) Evaluation of 
chemotherapy-induced apoptosis upon p65 knockdown in acute (48 hours), chronic EMT (24 days), and EMT 
memory (-7 days). U0126, ERK pathway inhibitor; SB203580, p38 inhibitor; LY294002, PI3K inhibitor; JNKi 
II, JNK inhibitor; BMS345541, IKK inhibitor; “U + J”, U0126 and JNKi II combination treatment. “-d/-h”, days/
hours after IL-1β withdrawal; “p”, previously treated with IL-1β. Cis, cisplatin; Doxr, doxorubicin. All results are 
reported as mean ± SEM. ****P < 0.0001. See also Fig. S4.
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To characterize histone modifications, we performed ChIP-qPCR and revealed temporal epigenetic alterations 
of the CDH1 promoter. Upon the acute IL-1β exposure, there was a reduction of active histone modifications 
including H3K9 acetylation (H3K9Ac) and H3K4 trimethylation (H3K4Me3), and an enrichment of the repres-
sive histone modification H3K27 trimethylation (H3K27Me3). These epigenetic alterations were enhanced in the 
continuous presence of IL-1β, persisted after IL-1β withdrawal, and eventually returned to basal levels, correlat-
ing with E-cadherin expression (Fig. 5A). Notably, two repressive histone modifications, H3K9 dimethylation 
(H3K9Me2) and H3K9 trimethylation (H3K9Me3), were only enriched in chronic EMT and in the early phase 
of EMT memory (Fig. 5A). Because H3K9Me2 and H3K9Me3 often co-existed with DNA methylation, we fur-
ther examined DNA methylation by methylation-specific PCR (MSP) and found increased methylated DNA in 
chronic EMT and EMT memory but not in acute EMT (Fig. 5B). Consistently with the memorized E-cadherin 
suppression, chronic TNF-α and TGF-β exposure also led to increased DNA methylation in the CDH1 promoter 
(Fig. S5A).
Figure 5. Dynamic epigenetic modifications of the CDH1 promoter in IL-1β-induced EMT. (A) Relative fold 
changes of histone modifications in different EMT stages compared to the untreated cells by ChIP-qPCR. (B) A 
representative picture of DNA electrophoresis showing the relative abundance of methylated (M, higher band) 
and unmethylated (U, lower band) DNA, examined by MSP. DNA methylation level was determined by the 
ratio of M band to U band in each sample. (C) SLUG level-dependent histone modifications compared to the 
untreated cells by ChIP-qPCR. (D) DNA methylation upon IL-1β exposure in HS and LS cells, examined by 
MSP. Values from ChIP-qPCR were in log scale and normalized to IgG control and Tubulin control at each time 
point. “-d”, days after IL-1β withdrawal; “p”, previously treated with IL-1β. See also Fig. S5.
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Next, we investigated the mechanism underlying these dynamic epigenetic modifications. Studies by Javaid 
et al. showed dynamic chromatin modifications in a system of Snail overexpression-induced EMT32. Others also 
reported that Snail could directly interact with histone methyltransferases such as G9a and SUV39H1 to sup-
press E-cadherin in breast cancer33,34. Because we found that the highly elevated SLUG level was essential for the 
establishment of chronic EMT and EMT memory, we postulated that SLUG mediated these epigenetic alterations 
upon IL-1β exposure. Utilizing the cells with partial SLUG knockdown, we found that compared to HS cells, LS 
cells contained more active histone modifications, such as H3K4Me3, and fewer repressive histone modifications, 
such as H3K27Me3 and H3K9Me2/3 in the CDH1 promoter (Fig. 5C). In addition, there was no increase of 
DNA methylation in LS cells despite the chronic IL-1β exposure (Fig. 5D). Next, we assessed the expression of 
the enzymes involved in these histone modifications as well as DNA methylation following IL-1β exposure but 
could not identify any targets (Fig. S5B). Although increased HDAC9 expression correlated well with decreased 
H3K9Ac, knockdown of HDAC9 failed to reverse E-cadherin expression, possibly due to the redundancy of 
HDACs (Fig. S5C). These findings demonstrate that H3K4 and H3K27 trimethylation as well as H3K9Ac are the 
immediate responders to IL-1β exposure, while H3K9 and DNA methylation only occurs following chronic IL-1β 
exposure. In addition, these epigenetic alterations in the CDH1 promoter are SLUG-dependent.
Blockade of epigenetic modifications restores E-cadherin expression and cellular sensitivity 
to chemotherapy in EMT memory. To determine the significance of these epigenetic modifications in 
the different stages of EMT, we chemically inhibited the relevant enzymes (Fig. 6A). Both the histone acetylation 
inhibitor (HDACi), Trichostatin A (TSA), and the H3K27Me3 inhibitor, EPZ-6438, blocked the downregulation 
of E-cadherin following the acute IL-1β exposure (Figs. 6B and S6A). In contrast, neither TSA nor EPZ-6438 
reversed E-cadherin expression in chronic EMT and EMT memory (Fig. 6C,D). Consistent with these findings, 
knockdown of EZH2, the enzyme predominantly responsible for H3K27Me3, impaired E-cadherin downreg-
ulation in acute EMT, but not in chronic EMT or EMT memory (Fig. S6B). A DNA methyltransferase inhib-
itor (DNMTi), 5-azacytidine-2′-deoxycytidine (decitabine), reversed E-cadherin expression in EMT memory 
(Fig. 6C). Inhibition of H3K9Me2/3 either by BIX01294 or genetic knockdown of SETDB1 or SUV39H1, two 
enzymes engaged in H3K9Me2/3, failed to reverse E-cadherin expression in EMT memory or chronic EMT 
(Figs. 6C,D and S6C). Of note, none of the chemical inhibitors were able to impair E-cadherin suppression in 
chronic EMT (Fig. 6D). These results indicate that following the IL-1β exposure, H3K27Me3 and H3K9Ac medi-
ate the downregulation of E-cadherin in acute EMT while DNA methylation is responsible for the E-cadherin 
suppression in EMT memory.
Next, we examined whether these epigenetic inhibitors could enhance chemotherapy-induced apoptosis in 
cells with EMT memory. Decitabine enhanced apoptosis induced by Etoposide, Doxorubicin, and SAHA not only 
in the epithelial cells, but also in the cells with chronic EMT and EMT memory. Notably, combination of decit-
abine with SAHA induced a comparable level of apoptosis in both the epithelial and mesenchymal cells (Fig. 6E). 
However, in combination with Cisplatin, decitabine had minimal effects, consistent with previous clinical find-
ings35. Together, these findings suggest that E-cadherin suppression in the different stages of IL-1β-induced 
EMT is driven by distinct epigenetic modifications. Inhibition of DNA methylation not only reverses E-cadherin 
expression but also increases the susceptibility to chemotherapy in these mesenchymal cells.
Overall, we have found SLUG-dependent epigenetic modifications of the CDH1 promoter following 
IL-1β-induced EMT. Upon acute IL-1β exposure, upregulated SLUG reduces the activating histone modifications, 
including H3K4Me3 and H3K9Ac, and promotes H3K27Me3, a suppressive histone modification. In the contin-
uous presence of IL-1β, SLUG accumulation leads to further enrichment of H3K27Me3 and de novo H3K9Me2/3 
as well as DNA methylation, which contributes to memorized E-cadherin suppression in EMT memory (Fig. 7).
Discussion
The elevated incidence of cancer and resulting mortality in patients with chronic inflammatory conditions 
highlight the significance of chronic inflammation in tumor initiation, progression, and metastasis. Preexisting 
chronic inflammation can predispose normal cells to environmental carcinogens by disrupting the biological 
barriers of normal tissue and also activate the intrinsic epigenetic machinery in epithelial cells, resulting in acti-
vation of oncogenes and/or inactivation of tumor suppressors2,36. Both precancerous and tumor cells can exploit 
deregulated cytokines in the TME, promoting growth through activation of downstream signaling, such as the 
ERK, JUN, and NF-κB pathways. These inflammatory pathways further promote cancer cell stemness, enhance 
resistance to environmental or therapeutic pressure, and facilitate metastasis18,37. In addition, immune cells in the 
TME are highly plastic and under the influence of inflammatory mediators, can be redirected to exert pro-tumor 
functions through multiple mechanisms, including induction of DNA damage by producing reactive oxygen 
species, suppression of immune responses by upregulating checkpoint molecules, and precipitation of metastasis 
by forming complexes with cancer cells36,38,39.
In this study, we found gradually progressing EMT phenotypes upon chronic cytokine exposure, followed by 
an EMT memory phenomenon in a subset of NSCLC cell lines. We observed that accumulation of the EMT tran-
scription factor SLUG was essential for the establishment of both chronic EMT and EMT memory. This molecular 
mechanism downregulating E-cadherin in acute EMT was not required for maintaining E-cadherin suppression 
in chronic EMT or EMT memory. The molecular difference was found to be attributed to dynamic epigenetic 
modifications. Inhibition of DNA methylation elevated E-cadherin expression during the EMT memory phase 
and enhanced sensitivity to chemotherapy agent-induced apoptosis in both chronic EMT and EMT memory.
Because transcriptional factors, such as SLUG and Fra-1, were required in acute EMT, it was anticipated that 
they also would be indispensable in chronic EMT and EMT memory. However, the maintenance of E-cadherin 
suppression in EMT memory relied on histone modifications and DNA methylation, independent of SLUG 
1 0Scientific RepoRtS |          (2020) 10:377  | https://doi.org/10.1038/s41598-019-57285-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
expression. Similarly, the NF-κB pathway, which mediated apoptosis resistance upon the acute IL-1β exposure, 
appeared not to be critical in chronic EMT and EMT memory. These findings suggest that inflammatory path-
ways regulate target gene expression and modulate tumor cell EMT in a complex temporal manner.
Whereas SLUG appears to be a major mediator of the epigenetic control of E-cadherin expression, the inter-
actions among different epigenetic modifications may also be important40,41. For example, H3K9 methylation and 
DNA methylation are considered to be highly interrelated, as evidenced by their co-existence in heterochroma-
tin and the direct interactions between H3K9 and DNA methyltransferases42,43. Several studies have provided 
Figure 6. Blockade of epigenetic modifications restores E-cadherin expression and cellular sensitivity to 
chemotherapy in EMT memory. (A) A schematic diagram of the experimental design. (B) Pre-treatment of TSA 
and EPZ prevented E-cadherin downregulation upon the acute IL-1β exposure. (C) AZA treatment restored 
E-cadherin expression in EMT memory. (D) Epigenetic inhibitors did not alter E-cadherin expression in chronic 
EMT. (E) Apoptosis markers were evaluated in chronic EMT and EMT memory following the combination of 
AZA and chemotherapy agents. Quantification of E-cadherin expression was normalized to samples without IL-1β 
exposure. Epi I, epigenetic inhibitors. AZA, 5′-azacytidine-2′-deoxycytidine (decitabine), DNA methyltransferase 
inhibitor; TSA, pan HDAC inhibitor; EPZ, EPZ-6438, EZH2 inhibitor; BIX, BIX01294, G9a inhibitor; OG-L, OG-
L002, LSD1 inhibitor. “p”, previously treated with IL-1β. “n.d.”, non-detectable. See also Fig. S6.
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evidence of the association between H3K27Me3 and DNA methylation: (i) promoters marked with H3K27Me3 
are able to gain de novo DNA methylation during embryogenesis and carcinogenesis44,45; (ii) biochemical stud-
ies demonstrated binding of DNMTs to EZH246; and (iii) co-occurrence and interaction between H3K27 and 
H3K9 methylation47,48. Concordantly, we have demonstrated that methylation of both H3K9 and DNA is elevated 
following the enrichment of H3K27Me3 upon chronic IL-1β exposure. Therefore, it is possible that the accu-
mulation of H3K27 contributes to the de novo H3K9 and DNA methylation. Genetic or chemical inhibition of 
H3K27Me3 could restore E-cadherin expression only in acute EMT but not in chronic EMT or EMT memory. 
These findings suggest a hierarchy of epigenetic events leading to E-cadherin silencing in EMT.
Given that the epigenetic regulation upon chronic IL-1β exposure is SLUG-level dependent, the decrease in 
H3K27Me3, H3K9Me2/3, and DNA methylation following IL-1β withdrawal is most likely due to inadequate 
SLUG levels, leading to gradual restoration of E-cadherin expression. This could be attributed to disappearance 
of the previously formed epigenetic modifications. It is also possible that these previously formed epigenetic 
modifications are diluted upon cell division because studies have shown that the de novo formation of epigenetic 
modifications can, in certain instances, be permanent. Bintu et al. demonstrated a dynamic epigenetic regula-
tion in gene suppression at a single-cell level utilizing time-lapse microscopy49. The authors found that arbitrary 
expression of embryonic ectoderm development (EED), a structural component functioning with EZH2, was 
sufficient to induce irreversible gene silencing. Higher expression of EED resulted in enrichment of H3K27Me3 
and H3K9Me3 and endowed more cells with permanent gene silencing. Future studies tracing these epigenetic 
alterations at single cell resolution in this inflammation-induced EMT model will address this possibility and 
further dissect the composition of the epigenetic machinery in maintaining gene silencing.
Although it is well known that EMT endows cells with metastatic capacity, analysis of tissue specimens from 
metastatic tumors often reveals cells with epithelial features. EMT plasticity therefore is proposed to temporally 
modify these properties by facilitating cellular responses to the microenvironmental stimuli that lead to mesen-
chymal phenotypes and metastatic behaviors23,24,27. In the current study, fading of EMT memory, accompanied by 
a gradual elevation of E-cadherin expression, is consistent with a profound EMT plasticity. In a case of acquired 
EMT, increased migration and invasion of tumor cells enable them to travel away from primary tumor sites, 
which also distance them from EMT-promoting stimuli, such as inflammatory factors in the primary TME. We 
propose that because of the memorized EMT phenotypes, these migratory cells are able to seed the metastatic 
spread to distant organ sites. Once colonizing at a distant organ, the metastatic cells require restoration of the 
epithelial phenotypes in order to establish macrometastasis. Thus, chronic inflammation-induced EMT mem-
ory may be responsible for the underlying mechanism enabling spatial-temporal EMT plasticity associated with 
metastatic competence.
In addition to the anti-proliferative effects of DNMTi and HDACi, we have found that a low dose of DNMTi 
combined with an HDACi induces significant apoptosis in cells with chronic EMT and EMT memory. A phase 
I/II clinical trial evaluating a combination of a low dose of the DNMTi decitabine and the HDACi entinostat 
demonstrated durable responses lasting more than one year in some patients with recurrent metastatic NSCLC50. 
There are also ongoing investigations assessing the efficacy of combining epigenetic therapies with other cancer 
treatments, such as chemotherapy or immunotherapy. In the above-mentioned trial, five patients were subse-
quently enrolled in anti-PD-1/PD-L1 therapies due to disease progression. All five patients achieved apparent 
clinical benefit50–52. Consistent with these findings, Topper et al. recently found that DNMTi and HDACi com-
bination therapy induced potent immune responses, including an enhanced interferon gamma signature, CD8 T 
Figure 7. A schematic model of SLUG-dependent epigenetic modifications of the CDH1 promoter following 
IL-1β exposure in A549 cells.
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cell infiltration, and PD-L1 expression in a murine NSCLC model, supporting the potential benefit of checkpoint 
inhibitor therapy following epigenetic therapies53. Larger clinical trials are underway, directly comparing the 
efficacy of the combination therapy to immunotherapy alone (NCT01935947, NCT02546986, NCT02437136).
Inflammation profoundly impacts tumor development, progression, and metastasis. Our current findings are 
consistent with the remarkable reduction of both lung cancer incidence (67%) and mortality (77%) demonstrated 
by IL-1β inhibition in the CANTOS trial13. Our studies amplify mechanistic insights implicating IL-1β-regulated 
chronic inflammation as a central component in carcinogenesis and metastasis. Thus, inhibition of this pathway 
may contribute to both prevention and treatment of NSCLC.
Materials and Methods
Cell lines and reagents. NSCLC cell lines A549, H460, and A427 were purchased from ATCC and cultured 
as previously described14. Cells with doxycycline-inducible shRNA were constructed as previously described54. 
Briefly, the SLUG shRNA constructs were recombined into pLentipuro3/BLOCK-iT-DEST. The resulting recom-
binant lentiviruses were produced by 293 T cells and transduced into cells with the Tet repressor protein from 
the pLenti0.3/EF/GW/IVS-Kozak-TetR-P2A-Bsd vector. Cells were selected in 2 µg/mL puromycin for 10 days. 
Cells with doxycycline-controlled SLUG overexpression were made by transducing the pLVX-Tet-off Advanced 
vector and Plvx-Tight-Puro vector (Clontech) and selected in 2 µg/mL puromycin for 10 days. All cell lines were 
routinely genotyped and tested for mycoplasma. Recombinant IL-1β was purchased from BD Pharmingen and 
used at 1 ng/ml unless stated otherwise. For chronic IL-1β treatment, cells were split and passaged every 3 to 4 
days with fresh IL-1β added to the medium.
Chemical treatment. For assessment of apoptosis resistance, cells were treated with either Cisplatin 
(50 µM), Etoposide (100 µM), Doxorubicin (20 µM), or SAHA (20 µM) for 24 hours. For pathway and epigenetic 
inhibition, cells were treated with inhibitors for 72 hours at the following concentrations: 50 nM for TSA, 1 uM 
for BMS345541 and BIX01294, 5 uM for U0126, SB203580, and 5-aza-2′-deoxycytidine, 10 uM for JNK inhibi-
tor II and LY294002, 20 uM for EPZ-6438, and 50 uM for OG-L002. U0126 was purchased from Cell Signaling 
Technology; NF-κB inhibitor BMS345541, histone deacetylase inhibitor Trichostatin A (TSA), and DNA meth-
ylation inhibitor 5-aza-2′-deoxycytidine (decitabine) from Sigma; AKT inhibitor LY294002, JNK inhibitor II, 
and p38 inhibitor SB203580 (SB) from Calbiochem; LSD1 inhibitor OG-L002, G9a inhibitor BIX01294, EZH2 
inhibitor EPZ-6438, and all four chemotherapy reagents were purchased from Selleckchem.
Transient transfection of siRNA. Cells were transfected in a 6-well plate with siRNA using Lipofectamine 
RNAiMAX (Life Technologies) at a final concentration of 15 nmol/L following overnight attachment. For tran-
sient gene repression, cells were cultured continuously for 72 hours with the proper treatments. For prolonged 
gene repression, cells were repeatedly transfected with siRNA every 4 days. SiRNA pools against SLUG, ZEB2 and 
Fra-1 were purchased from Dharmacon.
Western blot. Samples were prepared as previously stated55. Horseradish peroxidase-conjugated secondary 
antibodies (Bio-Rad, Hercules, CA) and enhanced chemiluminescence (ECL) reagent (Amersham Biosciences, 
Piscataway, NJ) were used for protein detection. Antibodies against phosphorylated-p65, p-MAPK, p-JNK(T183/
Y185), p-c-JUN(S73), c-JUN, p-p38, p-Fra-1, Fra-1, SLUG, β-actin, and α-tubulin were purchased from Cell 
Signaling Technology. Antibodies against E-cadherin and Vimentin were purchased from BD Pharmingen. The 
antibodies against cytokeratin 18 (CK18) and GAPDH were from Abcam and Advanced Immunochemical Inc, 
respectively.
Quantitative reverse transcription PCR. Total RNA and cDNA were prepared as previously stated56. 
Transcript levels were measured using a MyiQ Cycler (Bio-Rad). Taqman Probes for SNAI1, SLUG, ZEB1, ZEB2, 
TWIST1, CJUN, JUNB, CFOS, FRA1(FOSL1), FOSL2, and B2M were purchased from Life Technologies. Primers 
for DNMT1, DNMT2, DNMT3, EZH2, EHMT1, EHMT2, SETDB1, SUV39H, HDAC1, HDAC2, HDAC3, HDAC4, 
HDAC6, HDAC9, and GAPDH were obtained from PrimerBank and utilized with Cyber-Green-based qPCR sys-
tem. Amplification was carried out for 40 cycles of 15 seconds at 95 °C, 30 seconds at 55 °C and 30 seconds at 72 °C. 
All samples were run in triplicate, and the relative gene expression levels were determined by normalizing their 
expression to B2M or GAPDH. Expression data are presented as fold-change values relative to the normalized 
expression levels in a reference sample using the following equation: RQ = 2−ΔΔCt.
Proliferation assay. As an indication of cell viability and proliferation, cellular ATP levels were measured 
using the ATPlite 1step Luminescence Assay Kit (Perkin Elmer). A549 cells with the indicated IL-1β treatment 
were plated in 96-well plates at 1000 cells per well. Eight replicates for each condition were plated for each inde-
pendent experiment. ATP luminescence was assessed every 24 hours up to 72 hours. Readings at each time point 
were normalized to the reading obtained at baseline to control for plating differences.
AIG assay. A modified high-throughput cell transformation assay was utilized to evaluate soft agar colony 
growth as previously described56. Briefly, the cells were suspended in 0.4% agar and plated atop a thick layer of 
solidified 0.6% agar. A549 cells with the indicated IL-1β treatment were plated in 96-well plates at 750 cells per 
well. Cells were cultured in complete medium for a total of 14 days. Data were collected as previously described56. 
At least ten replicates for each condition were plated for each independent experiment.
Flow cytometry. Cells were trypsinized and washed with FACS buffer as previously indicated. PD-L1 anti-
body (BD Bioscience) was diluted at 1:100 and stained cells for 30 mins at RT. Cells were washed twice before 
analysis by flow cytometry (BD, LSRII).
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ChIP-qPCR. ChIP assays were performed based on the manufacturer’s protocol (Millipore). Briefly, 5 million cells 
were collected and cross-linked with 1% of formaldehyde at RT, followed by cell nucleus extraction. The cell 
lysate was then subjected to sonication and then incubated with 1ug of either IgG or the antibody of inter-
est overnight in the presence of magnetic protein A/G beads. Bound DNA-protein complexes were eluted 
and reverse-cross-linked after a series of washes. Quantitative-PCR assays were performed under stand-
ard conditions. The primers for the E-cadherin promoter were 5′- CCACGCACCCCCTCTCAGT -3′and 5′- 
GAGCGGGCTGGAGTCTGAAC -3′; for the negative control, the loci were 5′- TCTTGACCTCTCCGCATC -3′ 
and 5′-CAACAGGACGAATGTGACTG -3′.
Methylation specific PCR (MSP). MSP was performed using bisulfate-modified DNA under con-
ditions that have been previously described57. Briefly, genome DNA was extracted using the Genome 
DNA Extraction Kit (Zymo Research) and subjected to bisulfate conversion following the manufactur-
er’s protocol. The primers for the E-cadherin promoter were: 5′-TTAGGTTAGAGGGTTATCGCGT-3′ and 
5′-TAACTAAAAATTCACCTACCGAC-3′ for methylated DNA; 5′-TAATTTTAGGTTAGAGGGTTATTGT 
-3′and 5′-CACAACCAATCAACAACACA-3′ for non-methylated DNA. The PCR products were then electro-
phoresed on 2% agarose gels, stained with ethidium bromide, and visualized under UV illumination.
RNA sequencing and differential expressed genes. Cell lysates were harvested using 400 μLQiazole 
(Qiagen), and total RNA was extracted according to the manufacturer’s protocol (Zymo Research). Library 
was prepared and sequenced by Illumina Hiseq. 3000 at the UCLA Technology Center for Genomics and 
Bioinformatics. Single-end transcriptome reads were mapped to the Ensemble GRCh37 reference genome using 
Tophat2. HTSeq-count was used to count the reads for each gene58. EdgeR was then utilized to normalizeand iden-
tify differentially expressed genes based on negative binomial distribution. A gene was defined as differentially 
expressed between two conditions if i) its Benjamini and Hochberg based false discovery rate was less than 0.05, 
and ii) its fold change was more than 2. Average log-ratio expressions of identified differential expressed genes 
were then subjected to hierarchical cluster analysis by utilizing Cluster 3.0 with metric based on cosine similarity 
and average linkage in clustering approach. The sequencing data is accessible at GEO (GSE142620).
Pathway analysis. Gene Set Variant Analysis (GSVA) was utilized to derive the activity of interest pathway 
or gene set from the expression of involved genes at various time points59. The derived dynamic profile of pathway 
activities was then subjected to the time-course analysis by utilizing R package maSigPro to determine if tem-
poral profiles were statistically significant between the treatment and control conditions60. In brief, the analysis 
performed a two-step regression approach to determine the pathways whose activities were time dependent, and 
significant different between treatment and control groups. A pathway was identified being deregulated in the 
experimental compared to the control groups if (i) R-squared of the final regression model for its activities was 
>0.7, and (ii) Benjamini and Hochberg based false discover rates of the regression coefficients associated experi-
mental group were <1e−5. Furthermore, deregulated pathways were stratified into memory exhibiting group if its 
activities in experimental compared to the control groups remained more than 50% of their peak values 15 days 
after IL-1β withdrawal, otherwise they were defined as IL-1β sensitivity. Information regarding the gene members 
of total 10,611 gene sets was obtained from the Molecular signature database31.
TCGA lung adenocarcinoma data. RSEM normalized expression (level 2) and clinical information 
was downloaded from the data portal. SLUG expression levels were transformed to z-scores based on those 
observed in normal samples. Samples were categorized in three groups as high (z-score > 2), intermediate 
(−2 ≤ z-score ≤ 2) and low (z-score < −2) groups.
Statistical analysis. All statistical analyses were performed in Prism 6 (GraphPad, La Jolla, CA) unless oth-
erwise noted. Student two tailed t-test was utilized to determine the statistical significance between experimental 
conditions with the exception of those in our RNA sequencing analysis which is described above.
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